Biogen has said it hopes new “real world” data will ensure patients are not put off taking its key multiple sclerosis drug, Tecfidera because of stomach problems that can occur early in treatment.

The European Commission has pulled marketing authorisations for generic versions of Biogen’s oral multiple sclerosis therapy Tecfidera, after concluding that the brand qualifies for additional ...

Tecfidera (dimethyl fumarate) is a brand-name oral capsule that’s prescribed for certain types of multiple sclerosis (MS) and clinically isolated syndrome (CIS). Tecfidera has interactions with ...

Biogen Inc beat analysts' estimates for fourth-quarter profit and revenue on Tuesday, driven by demand for its muscle disease treatment Spinraza and top-selling multiple sclerosis drug Tecfidera.